Replies to post #125729 on Avid Bioservices Inc (CDMO)

[sulaco]

Which way is the data moving, dog?

In the first study presented, interim data from a Phase I trial evaluating bavituximab plus paclitaxel therapy in patients with HER2-negative metastatic breast cancer (MBC) showed that 85% of patients achieved an objective tumor response, including 15% of patients achieving a complete response (CR) measured in accordance with RECIST criteria.

OK, let me get this straight. You take 1,000 women with Her-2 negative METASTATIC breast cancer (a very tough breast cancer) and 850 (yes, 850) of them respond to Bavi, and 127 respond COMPLETELY to Bavi.

I'll take those roses any day of the week and twice on Sunday, dog.


Good luck,

Best,

Joe

[biopharm]

Correct.... but it should also be noted that around that time frame is when the "full speed" ahead negative attack ads came all targeting Peregrine Pharmaceuticals. I also think those were the days when Peregrine could have sold their soul and Bavi pipeline and "would" have reached that $10 target as prediected by Roth.

They didn't sell their soul... as they own "100%" of the pipeline... global rights.... IP all locked up around PS... this is exactly what makes Peregrine a nightmare to Big Pharma.

Peregrine taking a note from Frank Sinatra... as they are saying ... its "My Way"

I'll let them finish it their way.... because after seeing some of the things over the past year: I don't think the FDA .. or Big Pharma can stop them... and for that they are Pi$$ed

GLTA!